WO2023012552 - ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES
National phase entry is expected:
Publication Number
WO/2023/012552
Publication Date
09.02.2023
International Application No.
PCT/IB2022/056550
International Filing Date
15.07.2022
Title **
[English]
ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES
[French]
VÉHICULES COMPLEXES D’INCLUSION D’ANANDAMIDE CYCLODEXTRINE
Applicants **
CZAP RESEARCH AND DEVELOPMENT, LLC
1370 Trancas Street #350
Napa, California 94558, US
Inventors
CZAP, Al
1370 Trancas Street #350
Napa, California 94558, US
Priority Data
63/229,447
04.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2129 | |
| EPO | Filing, Examination | 19610 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 8605 |
Total: 31512 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention provides oral cyclodextrin inclusion complex formulations in which an anandamide cyclodextrin inclusion complex is provided together with enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon delivery of the formulation to a target tissue the enzyme is activated and releases the anandamide from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex formulations are provided in the form of time release formulations, treating or preventing a nitric oxide deficiency or a disease which can be treated or prevented by increasing endogenous nitric oxide levels in a mammal.[French]
La présente invention concerne des formulations par voie orale de complexe d’inclusion de cyclodextrine dans lesquelles un complexe d’inclusion d’anandamide cyclodextrine est fourni conjointement à une enzyme ayant une activité de dégradation de cyclodextrine capable de digérer la cyclodextrine, de sorte qu’à l’issue de l’administration de la formulation à un tissu cible, l’enzyme est activée et libère l’anandamide de la cavité cyclodextrine. Dans des aspects alternatifs, ces formulations de complexe d’inclusion de cyclodextrine sont fournies sous la forme de formulations à libération prolongée, de traitement ou de prévention d’une carence en oxyde nitrique ou d’une maladie qui peut être traitée ou prévenue par l'augmentation des taux endogènes d’oxyde nitrique chez un mammifère.